Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Jackey Suen, 09 Oct 2018

LCL161, an experimental inhibitor of apoptosis (IAP) protein antagonist, is shown to improve pathologic complete response (pCR) when added to paclitaxel in selected patients with localized triple-negative breast cancer (TNBC) in neoadjuvant settings.

01 Dec 2015
Colchine use in male Taiwanese patients with gout is associated with substantially reduced risk for cancer, as shown in a 12-year cohort study.

Weight gain ups cancer risk among middle-aged individuals

11 Jul 2018

Individuals who gain weight during middle life appear to be at greater risk of developing obesity-related cancer irrespective of metabolic function and body mass index (BMI), according to a study.

Researchers examined independent and combined effects of weight gain and metabolic dysfunction during middle-adult years on obesity-related cancer risk in a cohort of 3,850 individuals (aged 45–69 years) from the Framingham Offspring Study.

Obesity-related cancer outcomes included those that involved the female reproductive organs (postmenopausal breast, uterine/endometrial and ovarian), colon, rectum, stomach, liver, gallbladder, pancreas, kidney, thyroid, oesophageal adenocarcinoma, leukaemia, non-Hodgkin lymphoma and multiple myeloma.

During about 14 years of follow up, 145 men and 90 women lost ≥0.45 kg/years (mean weight loss, –0.72 and –0.77 lbs/year, respectively), and 530 men and 805 women gained 0.45 kg/year (mean weight gain, 0.81 and 0.80 kg/year, respectively). Weight remained stable in 1,166 men and 1,112 women.

Compared with maintaining stable weight, gaining ≥0.45 kg/year over about 14 years was associated with a 38-percent increased cancer risk (hazard ratio [HR], 1.38; 95 percent CI, 1.09–1.76). Of note, the elevated cancer risk associated with weight gain increased by 77 percent in men and women with metabolic dysfunction (HR, 1.77; 1.21–2.59).

Compared with nonoverweight adults, men and women who became overweight (BMI 30 and 25 kg/m2, respectively) during midlife also had increased cancer risk (men: HR, 2.18; 1.33–3.56; women: HR, 1.60; 1.12–2.28).

The risk increased by 28 percent and 33 percent, although not significantly, in men and women who were already overweight at baseline. This is despite having a midlife BMI that was higher by 3.4 kg/m2 than the midlife BMI of those who gained weight later.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Jackey Suen, 09 Oct 2018

LCL161, an experimental inhibitor of apoptosis (IAP) protein antagonist, is shown to improve pathologic complete response (pCR) when added to paclitaxel in selected patients with localized triple-negative breast cancer (TNBC) in neoadjuvant settings.

01 Dec 2015
Colchine use in male Taiwanese patients with gout is associated with substantially reduced risk for cancer, as shown in a 12-year cohort study.